This trial is conducted in Japan. The aim of this trial is to compare insulin aspart produced by current process and the NN2000 process in healthy Japanese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
34
Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Novo Nordisk Investigational Site
Tokyo, Japan
Area under the curve of insulin aspart concentration (AUC IAsp, 0-16h)
Time frame: From 0 to 16 hours after injection
Maximum insulin aspart concentration (Cmax IAsp)
Area under the curve of insulin aspart concentration (AUC IAsp)
Time to maximum insulin aspart concentration (tmax IAsp)
Terminal elimination half life (t½)
Body weight
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.